NCT05250908Active, not recruitingNot Applicable
A Prospective, Randomized Clinical Trial Evaluating INTIBIA, an Investigational Implantable Tibial Nerve Stimulator, Through 24-Months (INTIBIA Pivotal Study IU024)
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Coloplast A/S
- Enrollment
- 208
- Locations
- 22
- Primary Endpoint
- Response Rate
Study Overview
Brief Summary
Prospective, randomized, double-blind, multicenter study to evaluate the safety and efficacy of an implantable tibial nerve stimulator in subjects with urgency urinary incontinence (UUI).
Detailed Description
All eligible subjects will be implanted with the INTIBIA device. Subjects will be randomized to either INTIBIA therapeutic or INTIBIA non-therapeutic in a 2:1 ratio for the first 3 months of the study, at which point all subjects will receive therapeutic stimulation. Subjects will complete voiding diaries and questionnaires at Baseline and prior to each follow-up visit, which will occur at Months 3, 6, 12, and 24. Subjects will be offered to keep the device or have it explanted at the end of the study.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description
Subjects and investigator/site personnel are blinded until the Month 3 visit.
Eligibility Criteria
- Ages
- 22 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Women or men 22-80 years of age
- •Symptoms of overactive bladder with urgency urinary incontinence (UUI) demonstrated on a 72-hour voiding diary defined as a minimum of four (4) leaking episodes associated with urgency, and at least one leaking episode each 24-hour period
- •Greater than or equal to 6-month history of UUI diagnosis
- •Failure of conservative or behavioral therapy (e.g., bladder diet, timed voiding, bladder training, bladder control strategies, pelvic floor muscle training, fluid management)
- •Willing to abstain from OAB medications for the duration of the study
- •Willing to maintain a stable dose of all other medications that affect bladder function (e.g., tricyclic antidepressants) for at least four (4) weeks prior to beginning the baseline voiding diary and baseline questionnaires
- •Ambulatory and able to use the toilet independently and without difficulty
- •Willing and capable of providing informed consent
- •Willing and able to complete all procedures and follow-up visits indicated in the protocol
Exclusion Criteria
- •Diagnosis of stress urinary incontinence or mixed urinary incontinence, as confirmed by cough stress test and with a response of Yes to Q3 on the UDI-6 questionnaire
- •Current symptomatic urinary tract infection (UTI), urethritis, or more than three (3) UTIs in past year
- •Have post-void residual urine volume >30% of total voided volume
- •Inadequate skin integrity, any evidence of an infection, or lower leg edema limiting placement of device per physician discretion
- •Evidence of anatomic abnormalities that could jeopardize the placement of the device or pose a hazard to the subject
- •Prior treatment of urinary symptoms with nerve stimulation (e.g., percutaneous tibial nerve stimulation [PTNS] or sacral nerve stimulation [SNS])
- •History of chronic pain (e.g., chronic pelvic pain, fibromyalgia, Lyme disease, chronic back pain)
- •An active implantable electronic device regardless of whether stimulation is ON or OFF
- •Treatment of urinary symptoms with botulinum toxin therapy within six (6) months
- •Any neurological condition that could interfere with normal bladder or tibial nerve function, including debilitating stroke, epilepsy, multiple sclerosis, Parkinson's disease, peripheral neuropathy, fibromyalgia, or spinal cord injury (e.g., paraplegia)
- •Current urinary tract mechanical obstruction (e.g., benign prostatic enlargement or urethral stricture)
- •Other urinary tract dysfunction (e.g., abnormal upper urinary tract function, vesicoureteral reflux, bladder stone or tumor, urinary fistula)
- •End stage renal failure, GFR < 35, or dialysis
- •History of pelvic cancer requiring radiation or chemotherapy treatment within the past two years
- •Pelvic organ prolapse at or beyond the hymenal ring
- •Interstitial cystitis or bladder pain syndrome as defined by either American Urological Association (AUA) or European Association of Urology (EAU) guidelines prior to INTIBIA implant date
- •Diabetes with peripheral nerve compromise or uncontrolled diabetes
- •Pregnant as confirmed by urine or serum pregnancy test, plans to become pregnant over the study period, is less than one-year post-partum, is breast-feeding
- •Current active or a chronic systemic infection
- •Condition requiring magnetic resonance imaging (MRI) of lower leg
- •Condition requiring diathermy
- •Allergy to polyethylene terephthalate, silicone rubber, platinum, iridium, or polyurethane
- •Allergy to local anesthetic or adhesives
- •Deemed unsuitable for enrollment by the investigator based on history or physical examination (e.g., bleeding disorders, current anticoagulant medications)
- •Enrolled in another investigational or interventional device or drug trial over the study period
Arms & Interventions
INTIBIA Therapeutic
Experimental
Implanted with INTIBIA device and programmed to therapeutic stimulation for the duration of the study.
Intervention: INTIBIA Therapeutic (Device)
INTIBIA Non-Therapeutic
Experimental
Implanted with INTIBIA device and programmed to non-therapeutic stimulation for the first 3 months, then to therapeutic stimulation for the duration of the study.
Intervention: INTIBIA Non-Therapeutic (Device)
Outcomes
Primary Outcomes
Response Rate
Time Frame: 12 Months
≥50% reduction in UUUI episodes in the INTIBIA therapeutic group
Response Rate
Time Frame: 3 Months
≥50% reduction in UUI episodes between INTIBIA therapeutic and INTIBIA non-therapeutic
Secondary Outcomes
- Daily Voids(3 Months)
- Urgency Score(3 Months)
Investigators
Study Sites (22)
Loading locations...
Similar Trials
Completed
Not Applicable
T3 Certain Tapered With DCD vs T3 Certain Tapered Non-DCDEdentulous JawNCT04354688ZimVie60
Not yet recruiting
Phase 3
A Randomized Controlled Trial on the Efficacy and Safety of Butylphthalide in Reducing Myocardial Infarction Size and Improving Outcomes in STEMI Patients After Primary PCIST-segment Elevation Myocardial Infarction (STEMI)NCT06704685Xiangya Hospital of Central South University40
Not yet recruiting
Not Applicable
Trial for MicroPort's DCBCoronary Artery In-stent RestenosisNCT04386213Shanghai MicroPort Medical (Group) Co., Ltd.216
Not yet recruiting
Not Applicable
Safety and Efficacy of Polyvinyl Alcohol Sodium Acrylate Embolization Microspheres for CRLMColorectal Cancer Liver MetastasisNCT06021015Zhongda Hospital72
Suspended
Not Applicable
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of DepressionDepressive DisorderNCT01794559MYnd Analytics1,922